barzolvolimab   Click here for help

GtoPdb Ligand ID: 11607

Synonyms: CDX-0159
Compound class: Antibody
Comment: Barzolvolimab (CDX-0159) is a clinical stage humanized anti-KIT IgG1 monoclonal antibody that was developed by Celldex Therapeutics (as claimed in their patent US10781267B2) [2-3]. CDX-0159 is a variant of CDX-0158 (a.k.a. KTN0158 [4]) that was re-engineered to improve its safety profile and increase its serum half-life. CDX-0158 was originally designed for potential to treat GIST and other KIT-dependent tumours. This original version of the antibody inhibits mutant and wild type KIT phosphorylation, reduces mast cell degranulation and mast cell numbers, and shrinks tumours in a preclinical canine model of spontaneous mast cell tumour development [4].
References
1. Celldex. 
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints.
Accessed on 23/09/2026. Modified on 23/09/2026. celldex.com, https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and
2. Hadari Y, Mandel-Bausch EM Carr FJ, Jones TD, Perry LCA. (2020)
Anti-kit antibodies and uses thereof.
Patent number: US10781267B2. Assignee: Celldex Therapeutics Inc. Priority date: 25/07/2012. Publication date: 22/09/2020.
3. Kaur S, Kumaran MS, Singh S, Parsad D. (2026)
Beyond Omalizumab: Emerging Biologic and Small Molecule Therapies in Chronic Spontaneous Urticaria.
Clin Exp Allergy, [Epub ahead of print]. [PMID:42770623]
4. London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM et al.. (2017)
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.
Clin Cancer Res, 23 (10): 2565-2574. [PMID:27815356]
5. Terhorst-Molawi D, Hawro T, Grekowitz E, Kiefer L, Merchant K, Alvarado D, Thomas LJ, Hawthorne T, Crowley E, Heath-Chiozzi M et al.. (2023)
Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria.
Allergy, 78 (5): 1269-1279. [PMID:36385701]